The frequency of N- and K-ras oncogene mutations was investigated in plasma cell dyscrasias. Genomic DNAs from 128 patients were selected for this study: 30 monoclonal gammopathies of undetermined significance, 8 solitary plasmacytomas, 77 multiple myelomas (MM), and 13 plasma cell leukemias (PCL). A two-step experimental approach was devised. All samples were screened for mutations by single-strand conformation polymorphism analysis. DNA fragments displaying an altered electrophoretic mobility were further studied by direct sequencing to confirm and characterize the nature of the mutations. Ras mutations are not randomly distributed because they are detectable only in MM (9%) and PCL (30.7%). N-ras codons 12, 13, and 61 and K-ras codon 12 were found to be mutated, but N-ras codon 61 mutation was the most frequent finding (63.6%). In conclusion, ras mutations were found in PCL, and in a subset of MM characterized by advanced-stage disease and adverse prognostic parameters. Furthermore, based on our findings, it is possible to speculate that ras mutations represent a late molecular lesion in the process of multistep carcinogenesis.

Download full-text PDF

Source

Publication Analysis

Top Keywords

plasma cell
12
ras mutations
12
cell dyscrasias
8
mutations
6
mutational activation
4
activation k-ras
4
k-ras oncogenes
4
oncogenes plasma
4
dyscrasias frequency
4
frequency k-ras
4

Similar Publications

Carbonic anhydrases (CAs) are ubiquitous enzymes that catalyze reversibly both the hydration and dehydration reactions of CO and HCO-, respectively. Higher plants contain many different isoforms of CAs that can be classified into α-, β- and γ-type subfamilies. β-type CAs play a key role in the CO-concentrating mechanism, thereby contributing to efficient photosynthesis in the C plants in addition to many other biochemical reactions in plant metabolism.

View Article and Find Full Text PDF

An extracellular vesicle based hypothesis for the genesis of the polycystic kidney diseases.

Extracell Vesicle

December 2024

The Jared Grantham Kidney Institute at the University of Kansas Medical Center, Department of Nephrology and Hypertension, University of Kansas Medical Center, Kansas City, KS 66160, USA.

Autosomal dominant polycystic kidney (ADPKD) disease is the commonest genetic cause of kidney failure (affecting 1:800 individuals) and is due to heterozygous germline mutations in either of two genes, and . Homozygous germline mutations in are responsible for autosomal recessive polycystic kidney (ARPKD) disease a rare (1:20,000) but severe neonatal disease. The products of these three genes, (polycystin-1 (PC1 4302(3)aa)), (polycystin-2 (PC2 968aa)) and (fibrocystin (4074aa)) are all present on extracellular vesicles (EVs) termed, PKD-exosome-like vesicles (PKD-ELVs).

View Article and Find Full Text PDF

POEMS Syndrome Presenting as First-Time Heart Failure Exacerbation.

JACC Case Rep

January 2025

Department of Cardiovascular Medicine, Mayo Clinic, Rochester, Minnesota, USA.

We highlight the case of a 40-year-old man who presented with heart failure exacerbation and was ultimately discovered to have POEMS (polyneuropathy, organomegaly, endocrinopathy, monoclonal plasma cell disorder, and skin changes) syndrome.

View Article and Find Full Text PDF

Background: Whether medium-term increased water intake alone, or in combination with co-adjuvant nonexercise interventions aimed to expand blood volume (BV), improve the human cardiovascular phenotype and cardiorespiratory fitness remains unexplored.

Objectives: The purpose of this study was to determine the medium-term impact of increased (+40%) fluid (water) intake (IFI) or IFI plus head-up sleep (IFI + HUS) on BV and the cardiovascular phenotype in healthy individuals.

Methods: Healthy adults (n = 35, age 42 ± 18 years, 51% female) matched by sex, age, body composition, physical activity, and cardiorespiratory fitness were randomly allocated to IFI or IFI + HUS for 3 months.

View Article and Find Full Text PDF

Objective: The arginase inhibitor INCB001158 was evaluated for safety (primary endpoint) in locally advanced or metastatic solid tumours; pharmacokinetics, pharmacodynamics and efficacy were also assessed.

Methods And Analysis: In this non-randomised, open-label, three-part phase 1 study, INCB001158 was orally administered two times per day as monotherapy or in combination with intravenous pembrolizumab 200 mg every 3 weeks. Dose expansion was conducted in tumour-type cohorts (with or without prior anti-PD-1/PD-L1 (programmed death protein 1/programmed death ligand 1) therapy).

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!